Dataset Information


Renin-angiotensin system at the interface of COVID-19 infection.

ABSTRACT: Angiotensin-converting enzyme 2 (ACE2) has been recognized as a potential entry receptor for SARS-CoV-2 infection. Binding of SARS-CoV-2 to ACE2 allows engagement with pulmonary epithelial cells and pulmonary infection with the virus. ACE2 is an essential component of renin-angiotensin system (RAS), and involved in promoting protective effects to counter-regulate angiotensin (Ang) II-induced pathogenesis. The use of angiotensin receptor blockers (ARBs) and ACE inhibitors (ACEIs) was implicitly negated during the early phase of COVID-19 pandemic, considering the role of these antihypertensive agents in enhancing ACE2 expression thereby promoting the susceptibility to SARS-CoV-2. However, no clinical data has supported this assumption, but indeed evidence demonstrates that ACEIs and ARBs, besides their cardioprotective effects in COVID-19 patients with cardiovascular diseases, might also be beneficial in acute lung injuries by preserving the ACE2 function and switching the balance from deleterious ACE/Ang II/AT1 receptor axis towards a protective ACE2/Ang (1-7)/Mas receptor axis.

PROVIDER: S-EPMC7568848 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC7703541 | BioStudies
| S-EPMC7993901 | BioStudies
| S-EPMC8014665 | BioStudies
| S-EPMC7184165 | BioStudies
| S-EPMC8129173 | BioStudies
| S-EPMC7377983 | BioStudies
| S-EPMC7236734 | BioStudies
| S-EPMC7256451 | BioStudies
| S-EPMC7908946 | BioStudies
| S-EPMC7314689 | BioStudies